SLNCF Silence Therapeutics plc

BEARISH Impact: 6/10 424B5
Horizon days Filed May 27, 2026 Processed 16d 19h ago SEC 0001193125-26-242060
Notable filing: 424B5
Latest settled — T+5d ⚠ clustered
SLNCF ▲ 0.00% at T+5d
SHORT call ✗ call lost 0.00% · α vs SPY +0.32% · entry $1.06 → $1.06
Next anchor: T+20d in 12d
Currently $1.06 · +0.00% from $1.06 entry (call sign-flipped)
Entry anchored
May 27, 2026
via day open
T+1d
0.00%
call 0.00% · α +0.24%
$1.06
settled 16d ago
T+5d
0.00%
call 0.00% · α +0.32%
$1.06
settled 10d ago
T+20d
call — · α —
in 12d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Silence Therapeutics filed a prospectus supplement to activate an at-the-market (ATM) offering of up to $100M in ADSs through Jefferies. The ATM allows the company to sell shares opportunistically, creating immediate dilution of $3.98 per ADS at the assumed price of $6.10. The company had only $70.1M in cash and minimal revenue ($0.4M) as of March 31, 2026, and is burning cash ahead of Phase 2 data in August 2026.

Actionable Insight

The ATM creates overhang and likely near-term selling pressure as the company will need to raise funds to extend its cash runway. Monitor future 424B5 filings for actual sales activity; any disclosed sales will further pressure the stock. The Phase 2 SANRECO data in August 2026 is a key catalyst that could offset dilution if positive.

Key Facts

  • ATM offering of up to $100,000,000 in ADSs through Jefferies LLC
  • Jefferies receives 3.0% commission on gross sales price
  • Immediate dilution of $3.98 per ADS to new investors
  • Net tangible book value per ADS: $0.82 before offering, $2.12 after (assuming full $100M at $6.10/ADS)
  • Stock closed at $6.64 on May 26, 2026 vs. assumed offering price of $6.10 per ADS
  • Company had $70.1M cash and $0.4M revenue in Q1 2026, with a net loss of $15.0M

Financial Impact

Potential dilution of up to ~35% of outstanding shares (16.4M ADSs vs 47.2M outstanding) at maximum $100M offering, reducing existing holders' ownership stake

dilutionshare_pricecash_runway

Risk Factors

  • Continuous ATM sales may depress stock price
  • Dilution of up to 35% if fully utilized
  • Company has minimal revenue and is pre-commercial; cash burn continues

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-242060
Document: 0001193125-26-242060-index-headers.html0001193125-26-242060
Document: 0001193125-26-242060-index.html0001193125-26-242060
Document: 0001193125-26-242060.txt0001193125-26-242060
4 reports for SLNCF
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SLNCF — sortable, filterable
Type Now
May 28, 2026
16d ago
EFFECT
BEARISH ★ 5/10
$1.06 $1.06· 0.00%▲ +0.32%$1.06 (+0.00%)
May 27, 2026
16d ago
424B5
BEARISH ★ 6/10
$1.06 $1.06· 0.00%▲ +0.32%$1.06 (+0.00%)
May 18, 2026
25d ago
S-3
BEARISH ★ 6/10
$1.45 $1.06▲ +27.02%▲ +29.32%$1.06 (+27.02%)
May 7, 2026
5w ago
8-K
NEUTRAL ★ 4/10
$2.63 $1.45▼ −44.77%▼ −46.28%$1.06 (−59.70%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (45h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access